“The third quarter saw a series of meaningful achievements,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics (VTVT). “During the quarter, we randomized our first patient in the Phase 3 CATT1 trial, expanded our U.S. patent estate for cadisegliatin, and successfully completed an $80 million private placement financing with leading healthcare investors. With a strengthened balance sheet, we are positioned to continue advancing our cadisegliatin program and remain on track to report topline results from the CATT1 trial in the second half of 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics trading resumes
- vTv Therapeutics trading halted, volatility trading pause
- vTv Therapeutics’ Promising Phase 3 Study on Cadisegliatin for Type 1 Diabetes
- vTv Therapeutics announces three appointments to Scientific Advisory Board
- vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders